Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia

NCT04542044 | Completed

• 1 other identifier: CCER2020-01518
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the strategy of investigators for outpatients SARS-CoV-2 moderate pneumonia management in terms of efficacy and patient safety. The investigators ultimate goal is to validate first wave management strategy in order to support the investigators future approach in the event of a second wave, and spare the hospital resources by safely keeping at home as many patients as possible.

Conditions

Covid19; Pneumonia

Outcome Measures

Primary Outcomes (1)

• Secondary hospitalization(s) or death COVID-19 related

  30 to 60 days from diagnosis

Secondary Outcomes (3)

• severity of COVID-19 disease

  30 to 60 days from diagnosis

• patient satisfaction with management strategies

  30 to 60 days from diagnosis

• Saved costs

  30 days

Interventions

management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia OTHER

Data collected with a cohorte of SARS-CoV-2 pneumonia in an outpatient basis

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with SARS-CoV-2 pneumonia without hospitalization criteria at primary consultation

You may qualify if:

• All persons with suspected or confirmed SARS-CoV-2 pneumonia who consulted in the emergency department of the HUG without criteria for hospitalization4 (Pneumonia with CURB-65 \>= 2 or new O2 dependency or increased O2 requirements or sustained respiratory rate≥20 min or decompensated comorbidity or major alteration of the general state) and who have been scheduled for outpatient follow-up in HUG.

You may not qualify if:

• Patients with hospitalization criteria
• Refusal to consent documentation found in the computerized patient record or oral refusal consent during follow up call.

Sponsors & Collaborators

• University Hospital, Geneva: lead

Study Sites (1)

Geneva University Hospital

Geneva, Switzerland

Location

MeSH Terms

Conditions

COVID-19; Pneumonia

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief resident

Study Record Dates

• First Submitted: September 2, 2020
• First Posted: September 9, 2020
• Study Start: April 2, 2020
• Primary Completion: May 5, 2020
• Study Completion: June 30, 2020
• Last Updated: September 9, 2020

Record last verified: 2020-09

Data Sharing

• IPD Sharing: Will not share

Locations

CH (1)